Home > Liquid Biopsy

Stroma Liquid Biopsy

A NEW VIEW OF LIQUID BIOPSY
Stroma Liquid Biopsy - The Next Wave Of Proteomic Profiles For Cancer Biomarkers

While the landscape of cancer-associated DNA mutations has supported the initial concepts for liquid biopsy, it is now overwhelmingly apparent that throughout cancer progression, there are necessary adaptive microenvironments to support metastatic disease. We now present evidence that some of the essential interactions between stroma and proliferating cells can in part, be monitored through the protein response that tracks into the vascularized tumor and re-proportions the extracellular proteins (serum) found in the general blood circulation. These proteomic patterns can now be reported as a Stroma Liquid Biopsy™ which we are launching as a business unit called Rakta.


Is there a common systemic response to cancer? Coagulation, Complement Cascade, Acute Phase Inflammation

Our commercial goal is to associate this knowledge and data to establish relationships with client supplied samples characterized for progressive disease or response to therapies, ultimately achieving biomarkers useful in the clinic. We achieve these goals through partnerships and collaborations in the oncology field, but the discovery patterns can be applied to other disease pathologies.



Seed & Soil

  • Heterogeneous nature of cancer’s DNA
  • Characterize the stroma
  • Analyze tumor-associated microenvironment
  • Genomic and proteomic evidence
Learn more

No More Needle In The Haystack

  • Stroma and proliferating cell interaction
  • Monitor biomarker proteins
  • Highly observable measurements
Learn more

IP Supports Many New Cancer Management Strategies

  • Coagulation
  • Complement
  • Acute-phase Inflammation
Learn more

IP Supports Proteome Dysregulation In Cancer

  • Rakta Protein Panel
  • LC-MS Reporting Features
Learn more

New Cancer Targets

  • Inflammatory Response
  • Regulating factors
Learn more

IP Scope Is Vast

  • Triangle of Dysregulation
  • Personalized Medicine
Learn more

The Proteogenomic Goal

  • Characterize protease inhibitors
  • SERPIN inhibitors
Learn more

SERPIN Dysregulation in Cancer

  • Active & inactive SERPIN sub-populations
  • Partnerships and collaborations, SERPINs and cancer.
Learn more





References

1.Poster Reprint First Presented at New Jersey Cancer Retreat, May 25, 2017. Haiyan Zheng(1), Swapan Roy(2), Amenah Soherwardy(1), Seema Rahman(2), Matthew Kuruc(2); (1)Rutgers Center for Integrative Proteomics, Piscataway, NJ; (2)Biotech Support Group LLC, Monmouth Junction, NJ; entitled "Stroma Liquid Biopsy - Proteomic Profiles for Cancer Biomarkers" . Cell. 2011;144:646-674.


2.Zheng H, Zhao C, Roy S, et al. The Comparison of the Serum Proteome in Individuals with Cancers versus those without Cancer, and its application to Wellness. Poster reprint from 12th Annual US HUPO 2016 Conference, held March 13 – 16, 2016 Boston, MA, USA.


3.Zheng H, Zhao C, Roy S, et al. The Commonality of the Cancer Serum Proteome Phenotype as analyzed by LC-MS/MS, and Its Application to Monitor Dysregulated Wellness. Poster reprint from AACR Annual Meeting 2016 Conference, held April 17-20, 2016 New Orleans, LA USA

Contact Us

For Detailed Liquid Biopsy Whitepaper